MRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!

Overview

Journal Vaccines (Basel)

Date 2023 Mar 30

PMID 36992091

Authors

Vivek P Chavda

Gargi Jogi

Srusti Dave

Bhoomika M Patel

Lakshmi Vineela Nalla

Krishna Koradia

Affiliations

Soon will be listed here.

Abstract

mRNA vaccines take advantage of the mechanism that our cells use to produce proteins. Our cells produce proteins based on the knowledge contained in our DNA; each gene encodes a unique protein. The genetic information is essential, but cells cannot use it until mRNA molecules convert it into instructions for producing specific proteins. mRNA vaccinations provide ready-to-use mRNA instructions for constructing a specific protein. BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) both are newly approved mRNA-based COVID-19 vaccines that have shown excellent protection and efficacy. In total, there are five more mRNA-based vaccine candidates for COVID-19 under different phases of clinical development. This review is specifically focused on mRNA-based vaccines for COVID-19 covering its development, mechanism, and clinical aspects.

Citing Articles

Scrutinizing the COVID-19 vaccine safety debate.

Bin Abdulrahman K, Bin Abdulrahman A Hum Vaccin Immunother. 2024; 20(1):2401646.

PMID: 39693192 PMC: 11540079. DOI: 10.1080/21645515.2024.2401646.

The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems.

Parvin N, Mandal T, Joo S Pharmaceutics. 2024; 16(11).

PMID: 39598489 PMC: 11597542. DOI: 10.3390/pharmaceutics16111366.

Unveiling the promise: Exosomes as game-changers in anti-infective therapy.

Chavda V, Luo G, Bezbaruah R, Kalita T, Sarma A, Deka G Exploration (Beijing). 2024; 4(5):20230139.

PMID: 39439498 PMC: 11491308. DOI: 10.1002/EXP.20230139.

Nanoparticle-Mediated Mucosal Vaccination: Harnessing Nucleic Acids for Immune Enhancement.

Hussain W, Chaman S, Koser H, Aun S, Bibi Z, Pirzadi A Curr Microbiol. 2024; 81(9):279.

PMID: 39031239 DOI: 10.1007/s00284-024-03803-9.

Editorial: Nucleic acid-based therapies for cardiovascular diseases.

Martelli F, Mishra P, Caporali A Front Cardiovasc Med. 2024; 11:1392073.

PMID: 38586169 PMC: 10998467. DOI: 10.3389/fcvm.2024.1392073.

References

Chavda V, Vora L, Pandya A, Patravale V . Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. Drug Discov Today. 2021; 26(11):2619-2636. PMC: 8319039. DOI: 10.1016/j.drudis.2021.07.021. View

Choi A, Koch M, Wu K, Chu L, Ma L, Hill A . Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med. 2021; 27(11):2025-2031. PMC: 8604720. DOI: 10.1038/s41591-021-01527-y. View

Pardi N, Hogan M, Porter F, Weissman D . mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018; 17(4):261-279. PMC: 5906799. DOI: 10.1038/nrd.2017.243. View

Adam A, Shi Q, Wang B, Zou J, Mai J, Osman S . A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine. Transl Res. 2022; 249:13-27. PMC: 9173827. DOI: 10.1016/j.trsl.2022.06.004. View

Ssentongo P, Ssentongo A, Voleti N, Groff D, Sun A, Ba D . SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2022; 22(1):439. PMC: 9077344. DOI: 10.1186/s12879-022-07418-y. View

Chavda V, Bezbaruah R, Deka K, Nongrang L, Kalita T . The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. Vaccines (Basel). 2022; 10(11). PMC: 9698608. DOI: 10.3390/vaccines10111926. View

Zhao J, Zhao S, Ou J, Zhang J, Lan W, Guan W . COVID-19: Coronavirus Vaccine Development Updates. Front Immunol. 2021; 11:602256. PMC: 7785583. DOI: 10.3389/fimmu.2020.602256. View

Chavda V, Vuppu S, Mishra T, Kamaraj S, Patel A, Sharma N . Recent review of COVID-19 management: diagnosis, treatment and vaccination. Pharmacol Rep. 2022; 74(6):1120-1148. PMC: 9549062. DOI: 10.1007/s43440-022-00425-5. View

Kumar P, Sweeney T, Skabkin M, Skabkina O, Hellen C, Pestova T . Inhibition of translation by IFIT family members is determined by their ability to interact selectively with the 5'-terminal regions of cap0-, cap1- and 5'ppp- mRNAs. Nucleic Acids Res. 2013; 42(5):3228-45. PMC: 3950709. DOI: 10.1093/nar/gkt1321. View

10.

Chavda V, Soni S, Vora L, Soni S, Khadela A, Ajabiya J . mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics. Vaccines (Basel). 2022; 10(12). PMC: 9785933. DOI: 10.3390/vaccines10122150. View

11.

Jochum S, Kirste I, Hortsch S, Grunert V, Legault H, Eichenlaub U . Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial. Front Immunol. 2022; 12:798117. PMC: 8807632. DOI: 10.3389/fimmu.2021.798117. View

12.

Chavda V, Apostolopoulos V . COVID-19 vaccine design and vaccination strategy for emerging variants. Expert Rev Vaccines. 2022; 21(10):1359-1361. DOI: 10.1080/14760584.2022.2112571. View

13.

Hoerr I, Obst R, Rammensee H, Jung G . In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 1999; 30(1):1-7. DOI: 10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#. View

14.

Maruggi G, Zhang C, Li J, Ulmer J, Yu D . mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol Ther. 2019; 27(4):757-772. PMC: 6453507. DOI: 10.1016/j.ymthe.2019.01.020. View

15.

Chavda V, Bezbaruah R, Athalye M, Parikh P, Chhipa A, Patel S . Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. Viruses. 2022; 14(4). PMC: 9025561. DOI: 10.3390/v14040759. View

16.

Bezbaruah R, Chavda V, Nongrang L, Alom S, Deka K, Kalita T . Nanoparticle-Based Delivery Systems for Vaccines. Vaccines (Basel). 2022; 10(11). PMC: 9694785. DOI: 10.3390/vaccines10111946. View

17.

Ramachandran S, Satapathy S, Dutta T . Delivery Strategies for mRNA Vaccines. Pharmaceut Med. 2022; 36(1):11-20. PMC: 8801198. DOI: 10.1007/s40290-021-00417-5. View

18.

Haranaka M, Baber J, Ogama Y, Yamaji M, Aizawa M, Kogawara O . A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nat Commun. 2021; 12(1):7105. PMC: 8671474. DOI: 10.1038/s41467-021-27316-2. View

19.

Kon E, Elia U, Peer D . Principles for designing an optimal mRNA lipid nanoparticle vaccine. Curr Opin Biotechnol. 2021; 73:329-336. PMC: 8547895. DOI: 10.1016/j.copbio.2021.09.016. View

20.

Bloom K, van den Berg F, Arbuthnot P . Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2020; 28(3-4):117-129. PMC: 7580817. DOI: 10.1038/s41434-020-00204-y. View